A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder

Behavioral approaches are the main treatments for methamphetamine (MA) use disorder, and although they can be effective, many patients relapse (Vocci and Appel, 2007). Despite a number of clinical trials testing the efficacy of agents including dopamine partial agonists and GABAergic and serotonergic agents, there are no approved pharmacological treatments for MA use disorder (Elkashef et al., 2008; Karila et al., 2010). Early abstinence from MA is accompanied by intense drug craving and high levels of cognitive impairment (Potvin et al., 2018; Zorick et al., 2010), which are important factors in the maintenance of addiction and may undermine treatment efficacy.
Source: Drug and Alcohol Dependence - Category: Addiction Authors: Tags: Full length article Source Type: research